EyePoint Pharmaceuticals (EYPT) Cash from Operations: 2010-2019
Historic Cash from Operations for EyePoint Pharmaceuticals (EYPT) over the last 8 years, with Dec 2019 value amounting to -$20.8 million.
- EyePoint Pharmaceuticals' Cash from Operations fell 25753.09% to -$20.8 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$45.8 million, marking a year-over-year decrease of 67.12%. This contributed to the annual value of -$126.2 million for FY2024, which is 6832.05% down from last year.
- As of Q4 2019, EyePoint Pharmaceuticals' Cash from Operations stood at -$20.8 million, which was down 55.83% from -$13.3 million recorded in Q1 2019.
- Over the past 5 years, EyePoint Pharmaceuticals' Cash from Operations peaked at $81,000 during Q4 2018, and registered a low of -$20.8 million during Q4 2019.
- Its 3-year average for Cash from Operations is -$8.2 million, with a median of -$5.5 million in 2017.
- In the last 5 years, EyePoint Pharmaceuticals' Cash from Operations surged by 101.61% in 2018 and then slumped by 25,753.09% in 2019.
- Over the past 5 years, EyePoint Pharmaceuticals' Cash from Operations (Quarterly) stood at -$3.2 million in 2015, then crashed by 57.81% to -$5.0 million in 2016, then dropped by 0.58% to -$5.0 million in 2017, then spiked by 101.61% to $81,000 in 2018, then plummeted by 25,753.09% to -$20.8 million in 2019.
- Its last three reported values are -$20.8 million in Q4 2019, -$13.3 million for Q1 2019, and $81,000 during Q4 2018.